compounded semaglutide fda warning november 2025 The Risks of Products Novo Nordisk expands legal action

Pregnant or breastfeeding women should speak with a doctor first

Triple Agonist (GLP-1/GIP/Glucagon receptor agonist) Product Overview Retatrutide is a synthetic peptide engineered to simultaneously activate multiple metabolic hormone receptors

Staying informed about regulatory milestones, approval decisions, and coverage discussions helps Canadians make timely decisions about their weight management approach

Patients in states where WellMedr's licensed pharmacy partners may not hold the relevant state dispensing licensure - eligibility is confirmed during sign-up

While the shortage was originally expected to last until the end of October 2023 for the 1 mg pen only, Novo Nordisk (the manufacturer) has now expanded this to include both pens and extended the date to the end of March 2024

If you had to choose one or the other, the drug looks marginally better, though the difference wasnt statistically significant